Revenue growth accelerated to 46% with improving margins and a return to profitability. The termination of the ATM and new credit line suggest management sees no near-term capital need. Monitor Q4 peak-season sales and the signing of the new credit facility.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 13 $10.75entry
- T+1 · 6d ago +6.23%α +8.14% · $11.42
- T+5 · 2d ago +1.58%α +10.14% · $10.92
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmuCell reported Q3 2026 net income of $953,000 ($0.10/diluted share) versus a net loss of $140,000 in Q3 2025, with product sales up 46% to $8.0 million. The company also terminated its At-The-Market offering and is negotiating a new $3 million line of credit.
Key Financial Metrics
Key Facts
- Q3 2026 product sales $8.0M, up 46% from $5.5M in Q3 2025
- Net income $953,000 ($0.10/diluted) vs net loss $140,000 in Q3 2025
- Gross margin improved to 44.2% from 42.9%
- Adjusted EBITDA $1.9M vs $0.8M in Q3 2025
- Cash and equivalents $7.9M vs $3.8M at Dec 31, 2025
- Terminated At-The-Market offering
- Negotiating new $3M line of credit expected to sign in Q4 2026
Financial Impact
Revenue up 46% to $8.0M; net income swing of +$1.1M from loss to profit; cash increased $4.1M
Risk Factors
- Revenue growth partly aided by easy comp from prior-year distributor destocking
- Product development expenses shifted to COGS may pressure gross margins if not sustained
- Small market cap ($93M) amplifies volatility from any single-quarter variance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402176 |
Track record
8 reports on ICCC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 19, 20262d ago 8-K/A Bullish 5/10 Entry $11.27 Now $10.92 −3.13% settles Nov 30
- Nov 12, 20269d ago Press Release Bullish 5/10 Viewing Entry $10.75 to $10.92 Now $10.92 +1.58% ▲ +1.58% +10.14% vs SPY
- Oct 13, 20265w ago 8-K Bullish 6/10 Entry $10.79 to $10.45 Now $10.92 +1.20% ▼ −3.15% −2.00% vs SPY
- May 8, 202628w ago 8-K Bullish 4/10 Entry $8.45 to $9.91 Now $10.92 +29.23% ▲ +17.28% +17.36% vs SPY
- Apr 8, 202632w ago 8-K Bullish 7/10 No price data
- Apr 8, 202632w ago Press Release Mixed 6/10 Entry $7.19 to $7.54 Now $10.92 +51.88% ▲ +4.87% +1.68% vs SPY
- Mar 4, 202637w ago 8-K Mixed 6/10 Entry $6.35 to $6.63 Now $10.92 +71.97% ▲ +4.41% +6.65% vs SPY
- Mar 4, 202637w ago Press Release Mixed 6/10 Entry $6.35 to $6.63 Now $10.92 +71.97% ▲ +4.41% +6.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers